Taiwan · Delayed Price · Currency is TWD CH Biotech R&D Statistics
Total Valuation
CH Biotech R&D has a market cap or net worth of TWD 8.87 billion. The enterprise value is 9.14 billion.
| Market Cap | 8.87B |
| Enterprise Value | 9.14B |
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | Mar 26, 2026 |
Share Statistics
CH Biotech R&D has 102.80 million shares outstanding. The number of shares has decreased by -0.05% in one year.
| Current Share Class | 102.80M |
| Shares Outstanding | 102.80M |
| Shares Change (YoY) | -0.05% |
| Shares Change (QoQ) | +0.62% |
| Owned by Insiders (%) | 24.95% |
| Owned by Institutions (%) | 0.03% |
| Float | 34.72M |
Valuation Ratios
The trailing PE ratio is 19.18.
| PE Ratio | 19.18 |
| Forward PE | n/a |
| PS Ratio | 4.88 |
| PB Ratio | 3.30 |
| P/TBV Ratio | 3.32 |
| P/FCF Ratio | 19.05 |
| P/OCF Ratio | 15.06 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.98, with an EV/FCF ratio of 19.62.
| EV / Earnings | 19.70 |
| EV / Sales | 5.02 |
| EV / EBITDA | 10.98 |
| EV / EBIT | 14.74 |
| EV / FCF | 19.62 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.21 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 0.79 |
| Debt / FCF | 1.43 |
| Interest Coverage | 36.73 |
Financial Efficiency
Return on equity (ROE) is 17.39% and return on invested capital (ROIC) is 16.86%.
| Return on Equity (ROE) | 17.39% |
| Return on Assets (ROA) | 10.81% |
| Return on Invested Capital (ROIC) | 16.86% |
| Return on Capital Employed (ROCE) | 21.84% |
| Weighted Average Cost of Capital (WACC) | 4.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.12 |
Taxes
In the past 12 months, CH Biotech R&D has paid 105.09 million in taxes.
| Income Tax | 105.09M |
| Effective Tax Rate | 18.47% |
Stock Price Statistics
The stock price has increased by +5.24% in the last 52 weeks. The beta is 0.17, so CH Biotech R&D's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +5.24% |
| 50-Day Moving Average | 85.59 |
| 200-Day Moving Average | 92.97 |
| Relative Strength Index (RSI) | 51.48 |
| Average Volume (20 Days) | 380,355 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CH Biotech R&D had revenue of TWD 1.82 billion and earned 464.00 million in profits. Earnings per share was 4.50.
| Revenue | 1.82B |
| Gross Profit | 1.53B |
| Operating Income | 623.13M |
| Pretax Income | 568.87M |
| Net Income | 464.00M |
| EBITDA | 807.37M |
| EBIT | 623.13M |
| Earnings Per Share (EPS) | 4.50 |
Balance Sheet
The company has 397.27 million in cash and 664.33 million in debt, with a net cash position of -267.05 million or -2.60 per share.
| Cash & Cash Equivalents | 397.27M |
| Total Debt | 664.33M |
| Net Cash | -267.05M |
| Net Cash Per Share | -2.60 |
| Equity (Book Value) | 2.69B |
| Book Value Per Share | 26.13 |
| Working Capital | 150.08M |
Cash Flow
In the last 12 months, operating cash flow was 589.02 million and capital expenditures -123.34 million, giving a free cash flow of 465.68 million.
| Operating Cash Flow | 589.02M |
| Capital Expenditures | -123.34M |
| Depreciation & Amortization | 184.24M |
| Net Borrowing | -109.49M |
| Free Cash Flow | 465.68M |
| FCF Per Share | 4.53 |
Margins
Gross margin is 83.93%, with operating and profit margins of 34.25% and 25.51%.
| Gross Margin | 83.93% |
| Operating Margin | 34.25% |
| Pretax Margin | 31.27% |
| Profit Margin | 25.51% |
| EBITDA Margin | 44.38% |
| EBIT Margin | 34.25% |
| FCF Margin | 25.60% |
Dividends & Yields
This stock pays an annual dividend of 4.80, which amounts to a dividend yield of 5.56%.
| Dividend Per Share | 4.80 |
| Dividend Yield | 5.56% |
| Dividend Growth (YoY) | 17.07% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 90.84% |
| Buyback Yield | 0.05% |
| Shareholder Yield | 5.61% |
| Earnings Yield | 5.23% |
| FCF Yield | 5.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2022. It was a forward split with a ratio of 1.15.
| Last Split Date | Jul 26, 2022 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
CH Biotech R&D has an Altman Z-Score of 7.71 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.71 |
| Piotroski F-Score | 7 |